Beryl Drugs Reports Q1 Net Profit of Rs 2.11 Lakhs Amid Partial Manufacturing Suspension

1 min read Updated on 07 Aug 2025, 06:15 PM

Reviewed by

Shriram SScanX News Team

Overview

Beryl Drugs Limited announced a turnaround to profitability for Q1 ended June 30, with a net profit of Rs 2.11 lakhs compared to a net loss of Rs 36.79 lakhs in the previous year's Q1. Revenue from operations increased to Rs 483.58 lakhs from Rs 287.73 lakhs. The company's manufacturing facility is partially under suspension and upgradation, impacting the turnover for the entire quarter. Despite this, Beryl Drugs improved its financial performance significantly. Total expenses decreased to Rs 476.61 lakhs, and earnings per share stood at Rs 0.04.

*this image is generated using AI for illustrative purposes only.

Beryl Drugs Limited has announced its financial results for the quarter ended June 30, showing a turnaround to profitability despite challenges in its manufacturing operations.

Financial Highlights

Net profit of Rs 2.11 lakhs, compared to a net loss of Rs 36.79 lakhs in Q1 of the previous year
Revenue from operations increased to Rs 483.58 lakhs, up from Rs 287.73 lakhs in the corresponding quarter
Total expenses decreased to Rs 476.61 lakhs
Basic and diluted earnings per share stood at Rs 0.04

Operational Update

The company reported that its manufacturing facility is partially under suspension and upgradation, which has impacted the turnover for the entire quarter. Despite this challenge, Beryl Drugs managed to improve its financial performance significantly compared to the same period last year.

Revenue Breakdown

Particulars	Q1 (Rs in Lakhs)	Q1 (Rs in Lakhs)
Net sales	475.43	284.51
Other operating revenues	8.15	3.22
Total Revenue	483.58	287.73

Expense Analysis

Expense Category	Q1 (Rs in Lakhs)
Cost of materials consumed	230.87
Employee benefit expense	53.39
Finance costs	10.09
Depreciation and amortisation	35.08
Other Expenses	172.52

Management Commentary

The Board of Directors approved these unaudited financial results in their meeting. The company's management noted that the partial suspension of the manufacturing facility has affected the turnover for the entire quarter. However, they have not provided specific details on when the facility is expected to return to full operation or the potential impact on future quarters.

Auditor's Review

The financial results have been subjected to a limited review by the company's statutory auditors, Subhash Chand Jain Anurag & Associates. The auditors have not expressed any material concerns in their review report.

Looking Ahead

While Beryl Drugs has shown improvement in its financial performance, investors and stakeholders will likely be watching closely for updates on the manufacturing facility's upgradation and its impact on future quarters. The company's ability to maintain profitability and potentially increase revenues once the facility is fully operational will be key factors to monitor in the coming months.

Investors are advised to consider the ongoing operational challenges and their potential impact on future performance when making investment decisions related to Beryl Drugs Limited.

Historical Stock Returns for Beryl Drugs